written on 21.12.2017

PharmaBoardroom Releases New ‘Healthcare & Life Sciences Review Austria’ December 2017

TAGS: ,

PharmaBoardroom today releases its new 46-page Healthcare & Life Sciences Review Austria 2017.

With an admirable legacy of excellence behind it, Austria’s healthcare and life science industry is poised to take the next step and help make the country a genuine hub for both its region and for Europe.

Vienna is already fast establishing itself as Central Europe’s innovation hub as well as recently being ranked as the world’s most liveable city. High levels of education mean companies operational in Austria have access to a talented and competent workforce backed up by a supportive regulatory environment. A geostrategic location combined with logistical prowess is allowing Austria to leverage its manufacturing excellence – especially in the highly specialized field of biologics – and export more across Europe and the globe.

 Interviews

The report features in-depth interviews with:

  • Christa Wirthumer-Hoche, EMA and AGES
  • Alexander Biach, Hauptverband
  • Gerhard Hirczi, Vienna Business Agency
  • Peter Halwachs, LISAvienna
  • Jan Oliver Huber, PHARMIG
  • Barbara Rangetiner and Josef Weinberger, Octapharma
  • Ard van der Meij, Novartis
  • Albin Egger, UCB
  • Martin Spatz, IQVIA

 Quotes

“Austria is world reputed to be a stable, reliable, predictable country, both economically and politically, allowing operations to always run smoothly and that counts for a lot”

Karl-Heinz Hofbauer, Shire

“The human resource pool in Vienna is really well matched to the sorts of technical functions that our business requires”

Barbara Rangetiner, Octapharma

“I think there is a good balance in Austria between the healthcare system and the interests of pharmaceutical companies”

Astrid Muller, Biogen

“Austria in general has always been considered a reliable clinical trial destination due to the fact that global organizations understand there is a regulatory environment that promotes quick and easy access to patients”

Martin Spatz, IQVIA

Click here to register and download the report.